Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections

References

• Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706–15
   PubMed Web of Science ®Google Scholar
• Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999;27:97–132
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–85
   PubMed Web of Science ®Google Scholar
• Burke JP. Infection control - a problem for patient safety. N Engl J Med 2003;348:651–56
   PubMed Web of Science ®Google Scholar
• Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999;20:725–30
   PubMed Web of Science ®Google Scholar
• ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm 1999;56:1839–88
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins. Antibiotic prophyl-axis for gynecologic procedures. ACOG practice bulletin 23. Washington, DC, 2001
   Google Scholar
• Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA, eds. The Sanford Guide to Antimicrobial Therapy, 36th edn. Sperryville, VA: Antimicrobial Therapy, 2006; 51:125–7
   Google Scholar
• Anon. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther 2001;43:92–7
   PubMed Web of Science ®Google Scholar
• Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis 1994;18:422–7
   PubMed Web of Science ®Google Scholar
• Page CP, Bohnen JM, Fletcher JR, et al. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 1993;128:79–88
   Google Scholar
• Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592–8
   PubMed Web of Science ®Google Scholar
• McCollum M, Rhew DC, Parodi S. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003;25:3173–89
   Google Scholar
• Parodi S, Rhew DC, Goetz MB. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm 2003;9:317–26
   Google Scholar
• Li JZ, Willke RJ, Rittenhouse BE, et al. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt ) 2003;4: 57–70
   PubMedGoogle Scholar
• McKinnon PS, Sorensen SV, Liu LZ, et al. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006;40:1017–23
   PubMed Web of Science ®Google Scholar
• Sharpe JN, Shively EH, Polk HC, Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425–8
   PubMed Web of Science ®Google Scholar
• Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760–6
   PubMed Web of Science ®Google Scholar
• Platt R, Yokoe DS, Sands KE. Automated methods for surveillance of surgical site infections. Emerg Infect Dis 2001;7:212–16
   PubMedGoogle Scholar
• Platt R. Progress in surgical-site infection surveillance. Infect Control Hosp Epidemiol 2002;23:361–3
   PubMed Web of Science ®Google Scholar
• Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmaco-therapy 2001;21:263–74
   Google Scholar
• HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/HCUPnet/. Date accessed 5–30–06
   Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159–68
   PubMed Web of Science ®Google Scholar
• Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002;21:491–8
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003;47:1824–31
   PubMed Web of Science ®Google Scholar
• Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260–6
   PubMed Web of Science ®Google Scholar
• Zyvox (linezolid) [package insert]. New York, NY: Pharmacia & Upjohn, Division of Pfizer Inc; November 2005
   Google Scholar